Global Biologics Contract Manufacturing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Biologics Contract Manufacturing Market is presumed to reach the market size of nearly USD 47.92 Billion by 2032 from USD 16.77 Billion in 2023 with a CAGR of 11.07% under the study period 2024 - 2032.

Biologics contract manufacturing refers to the outsourcing of the production and manufacturing processes of biopharmaceutical products to specialized contract manufacturing organizations (CMOs). Biologics are complex therapeutic products derived from living organisms, such as proteins, antibodies, vaccines, and cell-based therapies. It allows pharmaceutical companies, biotechnology firms, and academic institutions to leverage the expertise, capabilities, and infrastructure of CMOs to efficiently and cost-effectively produce biologics on a large scale.

MARKET DYNAMICS

The increasing demand for biological drugs, driven by their efficacy and personalized medicine approaches, fuels the need for efficient manufacturing capabilities. Outsourcing biologics production to specialized contract manufacturing organizations (CMOs) offers cost efficiency and flexibility for pharmaceutical companies, allowing them to focus on core competencies and adjust production volumes based on demand. The stringent regulatory standards and quality assurance in this manufacturing are met by CMOs, ensuring compliance with regulations and maintaining product safety and efficacy. Technological advancements in bioprocessing further enhance the efficiency and productivity of biologics manufacturing, and collaborative partnerships between pharmaceutical companies and CMOs drive innovation and streamline processes. The global market expansion of the biopharmaceutical industry, along with the growing emphasis on biologics, reinforces the need for reliable and scalable solutions.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of biologics contract manufacturing. The growth and trends of biologics contract manufacturing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the biologics contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

MABs
Recombinant Protein
Others

By Indication

Oncology
Immunological Disorders
Cardiovascular Disorders (CVDs)
Hematological Disorders
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Biologics Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the biologics contract manufacturing market include Wuxi Biologics; Abzena Ltd.; FUJIFILM Diosynth Biotechnologies; BI BioXcellence; Lonza Group AG; Boehringer Ingelheim GmbH; Samsung Biologics; Abbvie; Catalent; Bioreliance; Eurofins CDMO; Thermo Fischer (Patheon). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112111512

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . BIOLOGICS CONTRACT MANUFACTURING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET ANALYSIS BY PRODUCT

5.1 Overview by Product
5.2 Historical and Forecast Data
5.3 Analysis by Product
5.4 MABs Historic and Forecast Sales by Regions
5.5 Recombinant Protein Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET ANALYSIS BY INDICATION

6.1 Overview by Indication
6.2 Historical and Forecast Data
6.3 Analysis by Indication
6.4 Oncology Historic and Forecast Sales by Regions
6.5 Immunological Disorders Historic and Forecast Sales by Regions
6.6 Cardiovascular Disorders (CVDs) Historic and Forecast Sales by Regions
6.7 Hematological Disorders Historic and Forecast Sales by Regions
6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE BIOLOGICS CONTRACT MANUFACTURING COMPANIES

8.1. Biologics Contract Manufacturing Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF BIOLOGICS CONTRACT MANUFACTURING INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Wuxi Biologics
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Abzena Ltd.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Fujifilm Diosynth Biotechnologies
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. BI BioXcellence
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Lonza Group AG
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Boehringer Ingelheim GmbH
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Samsung Biologics
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Abbvie
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Catalent
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Bioreliance
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
9.13. Eurofins CDMO
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments
9.14. Thermo Fischer (Patheon)
- 9.14.1. Company Overview
- 9.14.2. Company Revenue
- 9.14.3. Products
- 9.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies